Mohd Amer Alsamman1, Eric C Vecchio2, Khaled Shawwa3, Gabriel Acosta-Gonzales4, Murray B Resnick4, Steven F Moss5. 1. Division of Hospital Medicine, The Miriam Hospital, The Warren Alpert Medical School of Brown University, 164 Summit Avenue, Providence, RI, USA. 2. Internal Medicine, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI, 02903, USA. 3. Division of Nephrology and Hypertension, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA. 4. Department of Pathology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI, 02903, USA. 5. Division of Gastroenterology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI, 02903, USA. steven_moss@brown.edu.
Abstract
BACKGROUND: Declining Helicobacter pylori (H. pylori) eradication rates have prompted a switch in first-line therapy from standard triple (PPI, clarithromycin, and amoxicillin) to bismuth-based quadruple therapy. A caveat of the ACG 2017 H. pylori treatment guidelines was a paucity of recent US eradication data. AIM: To determine Rhode Island H. pylori eradication data, in the largest US study from the last two decades. METHODS: Electronic records were queried for patients with H. pylori infection diagnosed by pathology, urea breath test, or stool antigen from 2015 to 2017. Demographics, diagnostic test, treatment regimen, and test of cure were extracted. Eradication rates were calculated, and treatment regimens were compared. RESULTS: A total of 1710 patients were identified (64% female): 825 (46%) diagnosed by breath test, 755 (42%) by biopsy, and 191 (12%) by stool antigen. Full data were obtained on 1101 patients. Seven regimens were used: quadruple (64%), triple (25%), doxycycline quadruple (5%), and miscellaneous (6%). Quadruple was superior to triple: (85% vs. 75%, P = 0.002), quadruple 14 days versus triple 14 days (87% vs. 79%, P = 0.0052), quadruple 10 days versus triple 10 days (77% vs. 67%, P = 0.33). Increased therapy length improved eradication (quadruple 14 days vs. 10 days, 87% vs. 77%, P = 0.002; triple 14 days versus 10 days 79% vs. 67%, P = 0.13). Finally, substituting doxycycline for tetracycline yielded lower eradication (85% vs. 67%, P = 0.006). CONCLUSION: Quadruple therapy is superior to triple therapy within the Rhode Island population. Fourteen-day therapy achieves superior eradication compared to 10-day therapy, and doxycycline is inferior to tetracycline for quadruple therapy. Our findings support adherence to ACG and international guidelines advising 14-day quadruple therapy.
BACKGROUND: Declining Helicobacter pylori (H. pylori) eradication rates have prompted a switch in first-line therapy from standard triple (PPI, clarithromycin, and amoxicillin) to bismuth-based quadruple therapy. A caveat of the ACG 2017 H. pylori treatment guidelines was a paucity of recent US eradication data. AIM: To determine Rhode Island H. pylori eradication data, in the largest US study from the last two decades. METHODS: Electronic records were queried for patients with H. pyloriinfection diagnosed by pathology, urea breath test, or stool antigen from 2015 to 2017. Demographics, diagnostic test, treatment regimen, and test of cure were extracted. Eradication rates were calculated, and treatment regimens were compared. RESULTS: A total of 1710 patients were identified (64% female): 825 (46%) diagnosed by breath test, 755 (42%) by biopsy, and 191 (12%) by stool antigen. Full data were obtained on 1101 patients. Seven regimens were used: quadruple (64%), triple (25%), doxycycline quadruple (5%), and miscellaneous (6%). Quadruple was superior to triple: (85% vs. 75%, P = 0.002), quadruple 14 days versus triple 14 days (87% vs. 79%, P = 0.0052), quadruple 10 days versus triple 10 days (77% vs. 67%, P = 0.33). Increased therapy length improved eradication (quadruple 14 days vs. 10 days, 87% vs. 77%, P = 0.002; triple 14 days versus 10 days 79% vs. 67%, P = 0.13). Finally, substituting doxycycline for tetracycline yielded lower eradication (85% vs. 67%, P = 0.006). CONCLUSION: Quadruple therapy is superior to triple therapy within the Rhode Island population. Fourteen-day therapy achieves superior eradication compared to 10-day therapy, and doxycycline is inferior to tetracycline for quadruple therapy. Our findings support adherence to ACG and international guidelines advising 14-day quadruple therapy.
Entities:
Keywords:
Eradication therapy; Gastrointestinal infections; Helicobacter pylori; Stomach; USA
Authors: Carlo A Fallone; Naoki Chiba; Sander Veldhuyzen van Zanten; Lori Fischbach; Javier P Gisbert; Richard H Hunt; Nicola L Jones; Craig Render; Grigorios I Leontiadis; Paul Moayyedi; John K Marshall Journal: Gastroenterology Date: 2016-04-19 Impact factor: 22.682
Authors: P Malfertheiner; F Megraud; C A O'Morain; J P Gisbert; E J Kuipers; A T Axon; F Bazzoli; A Gasbarrini; J Atherton; D Y Graham; R Hunt; P Moayyedi; T Rokkas; M Rugge; M Selgrad; S Suerbaum; K Sugano; E M El-Omar Journal: Gut Date: 2016-10-05 Impact factor: 23.059
Authors: Jason Y Park; Kerry B Dunbar; Midori Mitui; Christina A Arnold; Dora M Lam-Himlin; Mark A Valasek; Irene Thung; Chinemerem Okwara; Elizabeth Coss; Byron Cryer; Christopher D Doern Journal: Dig Dis Sci Date: 2016-02-29 Impact factor: 3.199
Authors: Cesar O Salazar; Victor M Cardenas; Rita K Reddy; Delfina C Dominguez; Lindsey K Snyder; David Y Graham Journal: Helicobacter Date: 2012-06-04 Impact factor: 5.753
Authors: William M Duck; Jeremy Sobel; Janet M Pruckler; Qunsheng Song; David Swerdlow; Cindy Friedman; Alana Sulka; Balasubra Swaminathan; Tom Taylor; Mike Hoekstra; Patricia Griffin; Duane Smoot; Rick Peek; David C Metz; Peter B Bloom; Steven Goldschmidt; Julie Parsonnet; George Triadafilopoulos; Guillermo I Perez-Perez; Nimish Vakil; Peter Ernst; Steve Czinn; Donald Dunne; Ben D Gold Journal: Emerg Infect Dis Date: 2004-06 Impact factor: 6.883